

FORM 4**UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287
 Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
 Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person Stark David M. (Last) (First) (Middle) C/O Teva Pharmaceutical Industries Ltd. 124 Dvora HaNevi'a St.,	2. Issuer Name and Ticker or Trading Symbol Teva Pharmaceutical Industries Ltd. [TEVA]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director <input type="checkbox"/> 10% Owner <input checked="" type="checkbox"/> Officer (give title below) <input type="checkbox"/> Other (specify below) Exec. VP Chief Legal Officer
(Street) Tel Aviv L3 6944020	3. Date of Earliest Transaction (Month/Day/Year) 03/04/2022	4. If Amendment, Date Original Filed (Month/Day/Year)
(City) (State) (Zip)		6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Ordinary Shares ⁽¹⁾	03/04/2022		M		37,939	A	(2)	59,319.39	D	
Ordinary Shares ⁽¹⁾	03/04/2022		S ⁽³⁾		17,008 (4)	D	\$7.4825 (5)	42,311.39	D	
Ordinary Shares ⁽¹⁾	03/04/2022		M		13,930	A	(2)	56,241.39	D	
Ordinary Shares ⁽¹⁾	03/04/2022		S ⁽³⁾		6,246 (4)	D	\$7.4825 (5)	49,995.39	D	
Ordinary Shares ⁽¹⁾	03/05/2022		M		20,199	A	(2)	70,194.39	D	
Ordinary Shares ⁽¹⁾	03/07/2022		S ⁽³⁾		9,057 (4)	D	\$7.3667 (6)	61,137.39	D	

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V		(A)	(D)	Date Exercisable	Expiration Date	Title			
Restricted Share Units	(2)	03/04/2022		M		37,939		(7)	(7)	Ordinary Shares (1)	37,939	\$ 0	0	D
Restricted Share Units	(2)	03/04/2022		M		13,930		(8)	(8)	Ordinary Shares (1)	13,930	\$ 0	13,931	D
Restricted Share Units	(2)	03/04/2022		A		127,345		(9)	(9)	Ordinary Shares (1)	127,345	\$ 0	127,345	D
Restricted Share Units	(2)	03/05/2022		M		20,199		(10)	(10)	Ordinary Shares (1)	20,199	\$ 0	60,599	D

Explanation of Responses:

- (1) The Ordinary Shares may be represented by American Depository Shares, each of which currently represents one Ordinary Share.
- (2) Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
- (3) The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- (4) Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II.
- (5) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$7.40 to \$7.60, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.
- (6) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$7.30 to \$7.49, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.

- (7) Restricted share units were received on February 8, 2022 upon satisfaction of performance criteria and vested on March 4, 2022.
- (8) Restricted share units were granted on March 4, 2019, with 13,930 having vested on each of March 4, 2021 and March 4, 2022, and 13,931 vesting on March 4, 2023.
- (9) Restricted share units were granted on March 4, 2022, with 31,836 vesting on each of March 4, 2023, March 4, 2024 and March 4, 2025, and 31,837 vesting on March 4, 2026.
- (10) Restricted share units were granted on March 5, 2021, with 20,199 having vested on March 5, 2022, 20,199 vesting on each of March 5, 2023 and March 5, 2024, and 20,201 vesting on March 5, 2025.

/s/ Dov Bergwerk as attorney-in-fact for David M.
Stark

**Signature of Reporting Person

03/08/2022

Date

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.